Thursday 18 June 2026

The Pharma Letter Podcast — Episode 21 — Will radical new EU regs hobble industry?

Pharmaceutical
Simon Wentworth
31 March 2023
podcast-21-big

More on this story...

Pharmaceutical
EC plans would 'sabotage' pharma industry, trade group says
13 February 2023
Biotechnology
European regulator enhances warning on JAK blocker safety
31 March 2023
Biotechnology
New challenges to navigate to reach regulatory approval, report finds
5 April 2023
Pharmaceutical
European regulatory shake-up fails to impress, as expected
26 April 2023




More ones to watch >




Today's issue

F2G and Shionogi set up regulatory push for olorofim after Phase III win
Pharmaceutical
F2G and Shionogi set up regulatory push for olorofim after Phase III win
18 June 2026
Pharmaceutical
FDA approves first oral carbapenem therapy for cUTIs
17 June 2026
Pharmaceutical
PwC: Biopharma dealmaking rebounds as pharma races to fill pipeline gaps
17 June 2026
Biotechnology
Jazz Pharmaceuticals strikes research deal with AbCellera
17 June 2026
Biotechnology
Nuclidium bets on copper as radiopharma moves beyond alpha-versus-beta debate
17 June 2026
Pharmaceutical
Over 90% reduced death risk with treatment in subgroup for ultra rare TK2d disease
17 June 2026
Biotechnology
Vedana Therapeutics launches with $46 million Series A financing
17 June 2026


Company Spotlight

AbCellera
A Vancouver-based antibody discovery company that deploys high-throughput single-cell screening technology to identify and develop therapeutic antibodies across infectious disease, rare disease, and neurology.


More Features in Pharmaceutical

F2G and Shionogi set up regulatory push for olorofim after Phase III win
18 June 2026
FDA approves first oral carbapenem therapy for cUTIs
17 June 2026
PwC: Biopharma dealmaking rebounds as pharma races to fill pipeline gaps
17 June 2026
Over 90% reduced death risk with treatment in subgroup for ultra rare TK2d disease
17 June 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze